Home › Funds › ArrowMark Colorado Holdings LLC › RPRX
ArrowMark Colorado Holdings LLC position in RPRX
ROYALTY PHARMA PLC · Health Care
ArrowMark Colorado Holdings LLC reported holding 362,162 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$21.1M, representing 1.00% of its reported portfolio and ranking #10 among its reported holdings. ArrowMark Colorado Holdings LLC has disclosed RPRX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ArrowMark Colorado Holdings LLC's RPRX position evolved
ArrowMark Colorado Holdings LLC first disclosed a stake in RPRX in Q3 2024 at 71,750 shares (US$2.0M). The position peaked in Q3 2026 at 362,162 shares, worth US$21.1M. Across 9 filings, ArrowMark Colorado Holdings LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 362,162 shares valued at US$21.1M — a reduction of -4,037 shares quarter over quarter.. Notable position changes include a 443% increase in Q4 2024 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 71.75K | $2.03M | New |
| Q4 2024 | 389.45K | $9.93M | Add |
| Q1 2025 | 389.45K | $12.12M | Hold |
| Q2 2025 | 389.45K | $14.03M | Hold |
| Q3 2025 | 380.41K | $13.42M | Reduce |
| Q4 2025 | 367.50K | $14.20M | Reduce |
| Q1 2026 | 366.75K | $17.59M | Hold |
| Q2 2026 | 366.20K | $20.53M | Hold |
| Q3 2026 | 362.16K | $21.14M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 47 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.26M sh · $598.81M · Q3 2026
- Baillie Gifford & Co 9.15M sh · $534.11M · Q3 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 5.97M sh · $348.63M · Q3 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- EFG International AG 3.94M sh · $229.51M · Q3 2026
- Patient Capital Management, LLC 3.42M sh · $199.71M · Q3 2026
- Dorsey Asset Management, LLC 2.42M sh · $140.98M · Q3 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $96.68M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.52M sh · $88.60M · Q3 2026
More on ArrowMark Colorado Holdings LLC
FAQ
How long has ArrowMark Colorado Holdings LLC held RPRX?
ArrowMark Colorado Holdings LLC has disclosed RPRX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is ArrowMark Colorado Holdings LLC's current position in RPRX?
As of Q3 2026, ArrowMark Colorado Holdings LLC holds 362.16K shares of RPRX (ROYALTY PHARMA PLC), valued at $21.14M, representing 1.00% of its reported portfolio and ranking #10.
Has ArrowMark Colorado Holdings LLC been buying or selling RPRX?
In the latest 13F filing (Q3 2026), ArrowMark Colorado Holdings LLC reduced its position in RPRX. The position peaked in Q3 2026 at 362.16K shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.